Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Advances in Gerontology
Erschienen in: Advances in Gerontology 4/2021

01.10.2021 | COVID-19

Menopausal Hormonal Therapy and Breast Cancer

verfasst von: E. V. Bakhidze, A. V. Belyaeva, I. V. Berlev, V. N. Anisimov, A. M. Belyaev

Erschienen in: Advances in Gerontology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

The most common treatment for menopausal syndrome is menopausal hormone therapy (MHT), however, the safety of MHT, due to the risk of developing and recurrent breast cancer (BC), is still a matter of debate. The review presents the results of randomized cohort studies of this issue. It has been shown that MHT increases the risk of developing breast cancer and disease recurrence after treatment. The risk of breast cancer developing in women receiving MHT depends on body mass index (BMI), duration of hormone use, and dose of drugs, and is greater in thin women compared with women with increased BMI, and also greater in estrogen–progestin combined MHT users compared with estrogen-only users. It was found that hormone-dependent forms of cancer developed more often in women using MHT, but by the time of diagnosis, the disease was found in more advanced stages and metastases in lymph nodes were found more often when compared with patients who did not use MHT. Risk of breast cancer recurrence is less with low doses of vaginal estrogen. An alternative option for the relief of menopausal disorders in breast cancer patients during and after treatment is using of pineal gland hormone melatonin, since, along with its anti-aging properties, it is able to suppress cancer at the stages of initiation, progression, and metastasis and has the ability to reduce the toxic effects of anticancer drugs simultaneously increasing their effectiveness.
Literatur
1.
Anisimov, V.N., Melatonin and its place in modern medicine, Russ. Med. Zh., 2006, no. 4, pp. 269–274. http://​www.​rmj.​ru/​articles/​obshchie.​
2.
Anisimov, V.N. and Vinogradova, I.A., Starenie zhenskoi reproduktivnoi sistemy i melatonin (Aging of Female Reproductive System of Melatonin), St. Petersburg: Sistema, 2008.
3.
Bershtein, L.M., Gormonal’nyi kantserogenez (Hormonal Carcinogenesis), St. Petersburg: Nauka, 2000.
4.
Bryukhina, E. and Usol’tseva, E., Melatonin is the key to adaptation of the female body in climacteric syndrome, Vrach, 2016, no. 4, pp. 68–71.
5.
Gershanovich, M.L., Garin, A.M., Baltinya, D., et al., Results of a third clinical study of tamoxifen and toremifen in two different doses for treatment of wild-spread breast cancer in women with postmenopause, Vopr. Onkol., 1997, vol. 43, no. 6, pp. 587–595.PubMed
6.
Zlokachestvennye novoobrazovaniya v Rossii v 2018 godu (zabolevaemost’ i smertnost’) (Cases of Malignant Neoplasms in Russia in 2018: Morbidity and Mortality), Kaprin, A.D., Starinskii, and Petrova, G.V., Eds., Moscow: Mosk. Nauchno-Issled. Onkol. Inst. im. P.A. Gertsena, 2019.
7.
WHO Scientific Group on Research on the Menopause: World Health Organisation Technical Report Series No. 670, Geneva: World Health Org., 1989.
8.
Menopazuza i klimaktericheskoe sostoyanie u zhenshchiny: Klinicheskie rekomendatsii (Menopause and Climacteric State in a Woman: Clinical Guide), Moscow, 2016.
9.
Prilepskaya, V.N., Menopause syndrome: innovations in menopausal therapy, Russ. Med. Zh., Mat’ Ditya, 2017, no. 2, pp. 105–108.
10.
Serov, V.N., Prilepskaya, V.N., and Ovsyannikova, T.N., Rukovodstvo po ginekologicheskoi endokrinologii (Guide on Gynecological Endocrinology), Moscow: Medpress-Inform, 2008.
11.
Smetnik, V.P. and Konovalova, V.N., Hormone replacement therapy and breast cancer risk in postmenopausal women: an analysis of some epidemiological studies, Ross. Onkol. Zh., 2011, vol. 2, pp. 53–56.
12.
Sukhikh, G.T., Smetnik, V.P., and Andreeva, E.N., Menopausal hormone therapy and health maintenance of women: clinical guide, Probl. Reprod., 2016, pp. 8–9.
13.
Semiglazov, V.F., Paltuev, R.M., Semiglazov, V.V., et al., General St. Gallen-2015 guidelines for the treatment of early breast cancer (adapted by the experts of the Russian Society of Breast Oncologists), Opukholi Zhen. Reprod. Sist., 2015, vol. 11, no. 3, pp. 43–60.
14.
Axlund, S.D. and Sartorius, C.A., Progesterone regulation of stem and progenitor cells in normal and malignant breast, Mol. Cell. Endocrinol., 2012, vol. 24, no. 357, pp. 71–79.
15.
Batur, P., Blixen, C.E., Moore, H.C., et al., Menopausal hormone therapy (HT) in patients with breast cancer, Maturitas, 2006, vol. 20, no. 53, pp. 123–132.
16.
Bhattacharya, S., Patel, K.K., Dehari, D., et al., Melatonin and its ubiquitous anticancer effects, Mol. Cell. Biochem., 2019, vol. 462, nos. 1–2, pp. 133–155.
17.
Beral, V., et al., Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet, 2003, vol. 362, no. 9382, pp. 419–427.PubMed
18.
Beral, V., Reeves, G., Bull, D., and Green, J., For the Million Women Study Collaborators Breast cancer risk in relation to the interval between menopause and starting hormone therapy, J. Natl. Cancer Inst., 2011, vol. 103, pp. 296–305.PubMedPubMedCentral
19.
Bray, F., Ferlay, J., Soerjomataram, I., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA–Cancer J. Clin., 2018, vol. 68, no. 6, pp. 394–424.PubMed
20.
Chen, W.Y., Manson, J.E., Hankinson, S.E., et al., Unopposed estrogen therapy and the risk of invasive breast cancer, Arch. Int. Med., 2006, vol. 166, no. 9, pp. 1027–1032.
21.
22.
Cobin, R.H., Goodman, N.F., et al., American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update, Endocrinol. Pract., 2017, vol. 23, no. 7, pp. 869–880.
23.
Col, N.F., Kim, J.A., and Chlebowski, R.T., Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence, Breast Cancer Res., 2005, vol. 7, no. 4, pp. 535–540.
24.
Collaborative Group on Hormonal Factors in Breast Cancer, Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence, Lancet, 2019, vol. 394, pp. 1159–1168.PubMedCentral
25.
Curigliano, G., Burstein, H.J., Winer, E.P., et al., De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017, Ann. Oncol., 2017, vol. 28, no. 8, pp. 1700–1712.PubMedPubMedCentral
26.
DiSaia, P.J., Brewster, W.R., Ziogas, A., and Anton-Culver, H., Breast cancer survival and hormone replacement therapy: a cohort analysis, Am. J. Clin. Oncol., 2000, vol. 23, no. 6, pp. 541–545.PubMed
27.
Emons, G., Mustea, A., and Tempfer, C., Tamoxifen and endometrial cancer: a Janus-headed drug, Cancers (Basel), 2020, vol. 12, no. 9, p. 2535.PubMedCentral
28.
Fahlén, M., Fornander, T., and Johansson, H., Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomized trial, Eur. J. Cancer, 2013, vol. 49, no. 1, pp. 52–59.
29.
Fournier, A., Berrino, F., Riboli, E., et al., Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int. J. Cancer, 2005, vol. 114, no. 3, pp. 448–454.PubMed
30.
Fournier, A., Mesrine, S., Dossus, L., et al., Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort, Breast Cancer Res. Treat., 2014, vol. 145, pp. 535–543.PubMedPubMedCentral
31.
Godfrey, H.M., Armour, M., and McBride, K.A., Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: a systematic review and meta-analysis, Breast, 2019, vol. 47, pp. 43–55.
32.
Grady, D., Rubin, S.M., Petitti, D.B., et al., Hormone therapy to prevent disease and prolong life in postmenopausal women, Ann. Int. Med., 1992, vol. 117, no. 12, pp. 1016–1037.PubMed
33.
Greiser, C.M., Greiser, E.M., and Doren, M., Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials, Hum. Reprod. Update, 2005, vol. 11, pp. 561–573.PubMed
34.
Grodstein, F., Manson, J.E., Colditz, G.A., et al., A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease, Ann. Int. Med., 2000, vol. 133, pp. 933–941.PubMed
35.
Grosse, Y., Baan, R., Straif, K., et al., A review of human carcinogens—Part A: pharmaceuticals, Lancet Oncol., 2009, vol. 10, pp. 13–14.PubMed
36.
Holmberg, L., Anderson, H., et al., HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomized comparison: trial stopped, Lancet, 2004, vol. 363, no. 9407, pp. 453–455.PubMed
37.
Hong, J., Huang, J., Shen, L., et al., A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis, BMC Cancer, 2020, vol. 20, no. 1, p. 663.PubMedPubMedCentral
38.
Hunter, M.M., Huang, A.J., and Wallhagen, M.I., “I’m going to stay young”: belief in anti-aging efficacy of menopausal hormone therapy drives prolonged use despite medical risks, PLoS One, 2020, vol. 15, no. 5, p. e0233703.PubMedPubMedCentral
39.
Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy, IARC Monogr. Eval. Carcinog. Risks Hum., vol. 91, Lyon: Int. Agency Res. Cancer, 2008.
40.
Kumle, M., Declining breast cancer incidence and decreased HT use, Lancet, 2008, vol. 372, no. 9639, pp. 608–610.PubMed
41.
La Croix, A.Z., Chlebowski, R.T., Manson, J.E., et al., Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial, J.A.M.A., 2011, vol. 305, no. 13, pp. 1305–1314.
42.
Le Romancer, M., Poulard, C., Cohen, P., et al., Cracking the estrogen receptor’s posttranslational code in breast tumors, Endocrinol. Rev., 2011, vol. 32, no. 5, pp. 597–622.
43.
Li, F., Dou, J., Wei, L., et al., The selective estrogen receptor modulators in breast cancer prevention, Cancer Chemother. Pharmacol., 2016, vol. 77, no. 5, pp. 895–903.PubMed
44.
Lupo, M., Dains, J.E., and Madsen, L.T., Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients?, J. Adv. Pract. Oncol., 2015, vol. 6, no. 4, pp. 322–330.PubMedPubMedCentral
45.
Marsden, J., Whitehead, M., A’Hern, R., et al., Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?, Fertil. Steril., 2000, vol. 73, no. 2, pp. 292–299.PubMed
46.
UK Public Assessment Report: Hormone-Replacement Therapy: Safety Update, London: Med. Healthcare Prod. Regul. Agency, 2007.
47.
Meurer, L.N. and Lená, S., Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis, J. Fam. Pract., 2002, vol. 51, no. 12, pp. 1056–1062.PubMed
48.
Mudhune, G.H., Armour, M., and McBride, K.A., Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: a systematic review and meta-analysis, Breast, 2019, vol. 47, pp. 43–55.PubMed
49.
Murphy, L.C. and Leygue, E., The role of estrogen receptor-β in breast cancer, Semin. Reprod. Med., 2012, vol. 30, no. 1, pp. 5–13.PubMed
50.
Nelson, H.D., Smith, M.E., Griffin, J., and Fu, R., Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force, Ann. Int. Med., 2013, vol. 158, no. 8, pp. 604–614.PubMed
51.
North American Menopause Society, The 2012 hormone therapy position statement of: the North American Menopause Society, Menopause, 2012, vol. 19, no. 3, pp. 257–271.
52.
Figueiredo, J.C., Haile, R.W., Bernstein, L., et al., Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study, Breast Cancer Res. Treat., 2010, vol. 120, no. 1, pp. 175–183.PubMed
53.
Osborne, C.K., Tamoxifen in the treatment of breast cancer, N. Engl. J. Med., 1998, vol. 339, no. 22, pp. 1609–1618.PubMed
54.
Pinkerton, J.V. and Thomas, S., Use of SERMs for treatment in postmenopausal women, J. Steroid Biochem. Mol. Biol., 2014, vol. 142, pp. 142–154.PubMed
55.
Prentice, R.L., Chlebowski, R.T., Stefanick, M.L., et al., Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study, Am. J. Epidemiol., 2008, vol. 167, no. 12, pp. 1407–1415.PubMed
56.
Ravdin, P.M., Cronin, K.A., Howlader, N., et al., The decrease in breast-cancer incidence in 2003 in the United States, N. Engl. J. Med., 2007, vol. 356, no. 16, pp. 1670–1674.PubMed
57.
Reiter, R.J., Rosales-Corral, S.A., Tan, D.X., et al., Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis, Int. J. Mol. Sci., 2017, vol. 18, no. 4, p. 843.PubMedCentral
58.
Román, M., Sakshaug, S., Graff-Iversen, S., et al., Postmenopausal hormone therapy and the risk of breast cancer in Norway, Int. J. Cancer, 2016, vol. 138, no. 3, pp. 584–593.
59.
Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial, J.A.M.A., 2002, vol. 288, no. 3, pp. 321–333.PubMed
60.
Samavat, H. and Kurzer, M.S., Estrogen metabolism and breast cancer, Cancer Lett., 2015, vol. 356, pp. 231–243.PubMed
61.
Santen, R.J., Allred, D.C., Ardoin, S.P., et al., Postmenopausal hormone therapy: an endocrine society scientific statement, Clin. Endocrinol. Metab., 2010, vol. 95, no. 7, pp. s1–s66.
62.
Schoenaker, D.A., Jackson, C.A., Rowlands, J.V., and Mishra, G.D., Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents, Int. J. Epidemiol., 2014, vol. 43, pp. 1542–1562.PubMedPubMedCentral
63.
Stefanick, M.L., Anderson, G.L., Margolis, K.L., et al., Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy, J.A.M.A., 2006, vol. 295, no. 14, pp. 1647–1657.PubMed
64.
Treeck, O., Lattrich, C., Springwald, A., and Ortmann, O., Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells, Breast Cancer Res. Treat., 2010, vol. 120, no. 3, pp. 557–565.PubMed
65.
Verheul, H.A., Coelingh-Bennink, H.J., Kenemans, P., et al., Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies, Maturitas, 2000, vol. 36, pp. 1–17.PubMed
66.
van Hellemond, I.E.G., Geurts, S.M.E., and Tjan-Heijnen, V.C.G., Current status of extended adjuvant endocrine therapy in early stage breast cancer, Curr. Treat. Options Oncol., 2018, vol. 19, no. 5, p. 26.PubMedPubMedCentral
67.
von Schoultz, E., Rutqvist, L.E., et al., Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial, J. Nat. Cancer Inst., 2005, vol. 97, no. 7, pp. 533–535.PubMed
68.
Wang, K., Li, F., Chen, L., et al., Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies, Oncotarget, 2017, vol. 8, no. 46, pp. 81109–81124.PubMedPubMedCentral
69.
Warner, M. and Gustafsson J.-Å., The role of estrogen receptor β(ERβ) in malignant diseases—a new potential target for antiproliferative drugs in prevention and treatment of cancer, Biochem. Biophys. Res. Commun., 2010, vol. 396, no. 1, pp. 63–66.PubMed
70.
Yager, J.D. and Davidson, N.E., Estrogen carcinogenesis in breast cancer, N. Engl. J. Med., 2006, vol. 354, no. 3, pp. 270–282.PubMed
Metadaten
Titel
Menopausal Hormonal Therapy and Breast Cancer
verfasst von
E. V. Bakhidze
A. V. Belyaeva
I. V. Berlev
V. N. Anisimov
A. M. Belyaev
Publikationsdatum
01.10.2021
Verlag
Pleiades Publishing
Schlagwort
COVID-19
Erschienen in
Advances in Gerontology / Ausgabe 4/2021
Print ISSN: 2079-0570
Elektronische ISSN: 2079-0589
DOI
https://doi.org/10.1134/S2079057021040020

Weitere Artikel der Ausgabe 4/2021

Advances in Gerontology 4/2021 Zur Ausgabe

OriginalPaper

Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients

OriginalPaper

Let-7a, mir-9, mir-132, and mir-218 microRNA Expression in the Dorsomedial and Ventromedial Hypothalamic Nuclei during Aging in Rats

OriginalPaper

Patient Age and CYP2D6*4/CYP2D6*3 Genotype on Maximal Heart Rate in Patients after Acute Coronary Syndrome Treated with Bisoprolol

OriginalPaper

Relationship of Peptides and Long Non-Coding RNAs with Aging

OriginalPaper

Prevalence, Structure, and Risk Factors for Mental Disorders in Older People

OriginalPaper

Comprehensive Geriatric Assessment—Resolved and Unresolved Issues (Review)

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 49 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Wie der Klimawandel gefährliche Pilzinfektionen begünstigt

24.05.2024 Candida-Mykosen Nachrichten

Dass sich invasive Pilzinfektionen in letzter Zeit weltweit häufen, liegt wahrscheinlich auch am Klimawandel. Ausbrüche mit dem Hefepilz Candida auris stellen eine zunehmende Gefahr für Immungeschwächte dar – auch in Deutschland.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise